Globalization and Change in the Japanese Pharmaceutical Industry, 1990–2010

Maki Umemura

Chapter 10 in Comparative Responses to Globalization, 2013, pp 204-226 from Palgrave Macmillan

Abstract: Abstract In the 1990s, the Japanese pharmaceutical industry faced a crisis caused by the government’s decision to open the domestic market toforeign competition.1 Prior to the 1990s, Japan’s pharmaceutical firms had been sheltered by protectionist policies. In certain industries, such as automobile or consumer electronics, Japan had managed to develop competitive advantages over its American or European rivals. However, Japan was a second-tier player in the global pharmaceutical industry. Japan’s leading pharmaceutical firms were less R&D-oriented, launched few global blockbuster drugs, and recorded fewer sales (Table 10.1) compared to leading global firms in the United States, the United Kingdom, or Switzerland. Japan was a net importer of pharmaceuticals and largely remained a peripheral player in the global pharmaceutical industry.

Keywords: Japanese Market; United Nations Industrial Development Organization; Liberal Market Economy; Pharmaceutical Affair; Coordinate Market Economy (search for similar items in EconPapers)
Date: 2013
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pal:palchp:978-1-137-26363-6_10

Ordering information: This item can be ordered from
http://www.palgrave.com/9781137263636

DOI: 10.1057/9781137263636_10

Access Statistics for this chapter

More chapters in Palgrave Macmillan Books from Palgrave Macmillan
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().